Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Vividion Therapeutics, founded in 2013 and headquartered in San Diego, California, is a biotechnology company focused on developing innovative therapeutics for traditionally undruggable targets in oncology and immunology. The company leverages its proprietary platform, which combines chemical biology and synthetic chemistry, to create small molecule medicines for patients with critical unmet needs.
Since its inception, Vividion Therapeutics has made significant strides in the biotechnology sector, attracting substantial investment. The company has raised a total of $371.5 million in funding, demonstrating strong investor confidence in its approach and potential. In a notable development, Vividion Therapeutics was acquired by Bayer in August 2021 for a valuation between $1.5 billion and $2 billion, marking a significant milestone in the company's journey.
Given the recent acquisition by Bayer, the prospects of a Vividion Therapeutics IPO are uncertain. As a subsidiary of a larger pharmaceutical company, the likelihood of a public offering may have changed. However, it's important to note that we do not have any current information or reports regarding Vividion Therapeutics' IPO plans.
Factors that could influence any potential future IPO decision might include the company's progress in its drug development pipeline, market conditions in the biotechnology sector, and strategic decisions made by its parent company, Bayer. As always, investors interested in Vividion Therapeutics should conduct thorough research and consider the broader context of the biotechnology industry when evaluating investment opportunities.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Vividion Therapeutics' IPO prospects remain uncertain, investors eager to explore opportunities in the innovative therapeutics space don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the biotech and pharmaceutical sectors, including companies like Vividion Therapeutics, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from their growth and breakthroughs in drug discovery before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
